Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SBC Medical Group Holdings (SBCWW) Operating Income (2023 - 2025)

Historic Operating Income for SBC Medical Group Holdings (SBCWW) over the last 3 years, with Q3 2025 value amounting to $15.9 million.

  • SBC Medical Group Holdings' Operating Income rose 1479.36% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.4 million, marking a year-over-year decrease of 3373.72%. This contributed to the annual value of $70.3 million for FY2024, which is 50.43% down from last year.
  • As of Q3 2025, SBC Medical Group Holdings' Operating Income stood at $15.9 million, which was up 1479.36% from $14.6 million recorded in Q2 2025.
  • SBC Medical Group Holdings' 5-year Operating Income high stood at $27.3 million for Q2 2024, and its period low was -$473374.0 during Q2 2023.
  • Moreover, its 3-year median value for Operating Income was $15.9 million (2025), whereas its average is $15.3 million.
  • Data for SBC Medical Group Holdings' Operating Income shows a peak YoY increase of 639709.72% (in 2024) and a maximum YoY decrease of 8033.43% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows SBC Medical Group Holdings' Operating Income stood at $24.0 million in 2023, then tumbled by 80.33% to $4.7 million in 2024, then surged by 236.63% to $15.9 million in 2025.
  • Its last three reported values are $15.9 million in Q3 2025, $14.6 million for Q2 2025, and $24.2 million during Q1 2025.